Appili Therapeutics Inc. APLI.TO
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | 309.09% | 6.59% | 2,120.59% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 309.09% | 6.59% | 2,120.59% | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | 309.09% | 6.59% | 2,120.59% | -- |
| SG&A Expenses | 59.86% | 4.74% | -42.62% | -13.69% | -16.88% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.96% | 20.91% | -61.51% | -48.71% | -43.06% |
| Operating Income | -0.60% | -19.27% | 65.09% | 52.43% | 43.06% |
| Income Before Tax | -38.79% | -512.40% | -76.58% | -27.26% | 23.95% |
| Income Tax Expenses | -76.68% | 54.92% | 198.59% | 2,722.22% | -- |
| Earnings from Continuing Operations | -35.94% | -581.25% | -81.82% | -31.74% | 22.02% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -35.94% | -581.25% | -81.82% | -31.74% | 22.02% |
| EBIT | -0.60% | -19.27% | 65.09% | 52.43% | 43.06% |
| EBITDA | -0.75% | -19.37% | 65.13% | 52.50% | 43.12% |
| EPS Basic | -25.68% | -638.46% | -70.97% | -31.11% | 22.92% |
| Normalized Basic EPS | -28.89% | -566.67% | -65.00% | -28.57% | 25.00% |
| EPS Diluted | -25.68% | -638.46% | -70.97% | -31.11% | 22.92% |
| Normalized Diluted EPS | -28.89% | -566.67% | -65.00% | -28.57% | 25.00% |
| Average Basic Shares Outstanding | 9.15% | -9.47% | 5.85% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 9.15% | -9.47% | 5.85% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |